Faeth Therapeutics (FTH) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and platform focus

• Focuses on conditionally active antibodies that act specifically within the tumor microenvironment, leveraging pH sensitivity for reversible binding and reduced toxicity.

• Lead program is in Phase 1b of a Phase 1/2 study, with key data announced at ASCO and more expected by year-end.

• Platform includes both monoclonal and bispecific antibodies, all designed for conditional activity.

VISTA program and scientific rationale

• Lead target VISTA is crucial in immune regulation and shows synergistic effects with PD-1/PD-L1 inhibition.

• Previous VISTA-targeting antibodies faced toxicity (CRS) and short half-life; the current approach aims to overcome these issues using pH-sensitive antibodies.

• pH-sensitive design allows for tumor-specific action, minimizing off-tumor toxicity.

Clinical trial design and results

• Phase 1/2 study includes dose escalation (monotherapy and combo with Libtayo) and dose expansion phases.

• No dose-limiting toxicities observed; only mild, target-engagement CRS, and improved pharmacokinetics with weeks-long half-life.

• Early signs of in-tumor activity seen even in cold tumors, with notable responses in MSS endometrial and colon cancers.

• Dose expansion is testing 3 mg/kg and 15 mg/kg, with both doses expected to be pharmacologically relevant.